西姆特拉生物制药解决方案公司宣布战略性采购以扩大美国注射药物的生产能力-动脉网

Simtra BioPharma Solutions Announces Strategic Purchase to Expand U.S. Manufacturing Capacity for Injectable Medicines

CISION 等信源发布 2025-07-25 20:00



可切换为仅中文







Simtra positioned to become the first CDMO to offer commercial-scale drug product manufacturing of antibody-drug conjugates (ADCs) in the United States,

Simtra有望成为美国首家提供抗体药物偶联物（ADC）商业化规模药品生产的CDMO。

enabling customers to complete the entire supply chain domestically.

使客户能够在国内完成整个供应链。

PARSIPPANY, N.J.

帕西帕尼，新泽西州

，

July 25, 2025

2025年7月25日

/PRNewswire/ -- Simtra BioPharma Solutions, a leading global contract development and manufacturing (CDMO) specializing in injectable medicines, announced today the purchase from Cook Group of a 65-acre property (301 N. Curry

/PRNewswire/ -- 全球领先的注射药物合同开发与制造（CDMO）公司Simtra BioPharma Solutions今日宣布，已从Cook Group购买了一处位于301 N. Curry的65英亩物业。

Pike

派克

) with more than 300,000 square feet of available space for expansion under-roof near its existing manufacturing facility in

）在其现有制造设施附近拥有超过30万平方英尺的可扩展空间，

Bloomington, Indiana

布卢明顿，印第安纳州

。

Leveraging Simtra's experience and expertise in manufacturing next generation oncology treatments, including ADCs, at its site in Halle/Westfalen,

利用Simtra在哈勒/威斯特法伦工厂生产下一代肿瘤治疗药物（包括ADC）的经验和专业知识，

Germany

德国

, the addition of this site provides Simtra significant flexibility to rapidly expand its manufacturing footprint in

，新增这一站点为Simtra提供了显著的灵活性，可以迅速扩大其制造版图在

the United States

美国

to respond to growing capacity demands from both new and existing customers.

以应对来自新客户和现有客户不断增长的容量需求。

'This purchase gives us the foundation to grow with purpose, building the advanced injectable capacity our customers need while strengthening our presence in

“此次收购为我们提供了有目标地发展的基础，在增强我们客户所需的先进注射能力的同时，也加强了我们在

North America

北美

,' said

`，`说

Franco Negron

弗朗科·内格隆

, Chief Executive Officer, Simtra BioPharma Solutions. 'It reflects our long-term commitment to delivering vital injectable products and helping our customers navigate complex global supply chains.'

Simtra BioPharma Solutions首席执行官表示：“这反映了我们对提供重要的注射产品和帮助客户应对复杂全球供应链的长期承诺。”

Simtra is evaluating a project to design and install manufacturing lines at the site, including the Company's first U.S.-based commercial-scale capacity for oncology-focused injectable drug products. The facility would run isolator-based vial and prefilled syringe filling lines. Simtra's model allows for 'build-to-suit' solutions that meet the unique needs of individual customers and their products..

Simtra正在评估一个项目，旨在设计和安装现场的生产流水线，包括公司首个位于美国的、专注于肿瘤学的商业规模注射药物产品产能。该设施将运行基于隔离器的小瓶和预充式注射器填充线。Simtra的模式允许提供“量身定制”的解决方案，以满足不同客户的独特需求及其产品要求。

This purchase complements other previously announced investments in the Company's growth, including the

此次收购补充了公司增长的其他先前宣布的投资，包括

$250 million

2.5亿美元

construction project currently underway at Simtra's existing

辛姆特拉现有建筑项目正在施工中

Bloomington

布卢明顿

manufacturing site, and the recently completed $100+ million new production building and

制造基地，以及最近完成的超过1亿美元的新生产大楼和

$14 million

1400万美元

conjugation and purification suite being built in Halle/Westfalen,

正在哈勒/威斯特法伦建设的结合与纯化套件，

Germany

德国

. Together, the U.S. and German investments reflect a balanced, global approach to growth, ensuring Simtra can support customers across both continents.

美国和德国的投资共同反映了一种平衡的全球增长策略，确保Simtra能够为两大洲的客户提供支持。

Simtra will be working closely with

Simtra将与之紧密合作

Monroe County, Indiana

印第安纳州门罗县

officials on a phased development plan, and the Company will share additional details in the coming weeks.

官员们正在制定一个分阶段的发展计划，公司将在未来几周内分享更多细节。

About Simtra BioPharma Solutions

关于Simtra生物制药解决方案

As the premier, independently owned Contract Development Manufacturing Organization with more than 65 years of sterile injectable manufacturing expertise, Simtra BioPharma Solutions offers world-class cGMP sterile fill and finish, technical expertise, quality service, and a uniquely collaborative approach to support its customers' strategic objectives.

作为拥有超过65年无菌注射剂生产经验的首屈一指的独立合同开发制造组织，Simtra BioPharma Solutions 提供世界级的 cGMP 无菌灌装和包装、技术专长、质量服务，以及独特的协作方式，以支持客户的战略目标。

Biotech and pharmaceutical companies partner with Simtra when they need to take their molecule to market, whether launching an innovation globally, improving a formulation, or proactively mitigating risk to grow their business. Simtra's teams of tenured experts deliver tailored, flexible solutions to help customers consistently fulfill their product goals at the highest quality, so they get in the hands of the patients who need them most. .

生物技术和制药公司在需要将其分子推向市场时会与Simtra合作，无论是全球推出创新产品、改进配方，还是主动降低风险以推动业务增长。Simtra经验丰富的专家团队提供定制化、灵活的解决方案，帮助客户始终以最高质量实现其产品目标，从而让最需要的患者能够获得这些产品。

For more information, visit

欲了解更多信息，请访问

www.simtra.com

。

SOURCE Simtra BioPharma Solutions

来源：Simtra BioPharma Solutions

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻吗

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+